title: Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer?
authors: Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
authors: Corey J
authors: CJ
authors: Langer
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000201:enzymology*; D000077192:Adenocarcinoma of Lung; D000077716:Afatinib; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D008297:Male; D009154:Mutation; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D011799:Quinazolines; D000077716:Afatinib; D066246:ErbB Receptors